• Restore CFTR ProteinCompleted with Results

  Study to evaluate VX-561 in adults 18 years and older with cystic fibrosis , protocol number Vertex VX-561-101

  This study evaluated different doses of the drug VX-561 to determine safety and effectiveness.

  • Age:

    18 Years and Older

  • Mutation(s):

    One Copy F508del or No Copies F508del

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    8

  • Length of Participation:

    16 weeks

• Restore CFTR ProteinCompleted with Results

  Phase 2 study of CTP-656 in adults with CF who are currently taking ivacaftor (Kalydeco®) , protocol number Concert CTP-656

  This study evaluated the safety and effectiveness of the drug CTP-656 in adults with CF who have a gating mutation and are currently taking ivacaftor (Kalydeco®).

  • Age:

    18 Years and Older

  • Mutation(s):

    One Copy F508del or No Copies F508del

  • FEV1% Predicted:

    60% or greater

  • Number of Visits:

    6

  • Length of Participation:

    7 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.